Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PDSB has a second generation CV-19 vaccine to handle Variants!!!!!! EUA could have the vaccine ready next year for Brazil and South America
Plus 3 phase 2 Oncology Cancer Trials one with Merck one with NIH and one with MD Anderson Cancer center
CDC WARNS OF 'AVOIDABLE' SURGE...
Covid cases rise across more than half of USA...
ASTRA Jab Faces Fresh Setback as Feds Question Trial Data...
National Guard Soldiers transporting vaccines held at gunpoint ...
LOCKDOWNS RETURN IN EUROPE...
MERKEL: We are in new pandemic...
French hospitals 'violent shock'...
Sao Paulo reports record 1,021 deaths in 24 hours...
.
Just made a small fortune on another investment will be making small methodical buys today into PDSB. Added 23k today in 8 buys and will buy another 31k and then I'm locked in with 200k shares. Thank You! Stupid Market Makers!!.
PDSB has multi hundred dollar share price potential like NVAX or MRNA
PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of PDS0203 with an Award of up to ~US$60 Million
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/501-iotechnnouncesthatits19accineonsortium20210311n
PDSB Website
https://www.pdsbiotech.com/
PDSB March Biz Presentation
https://www.pdsbiotech.com/images/pdf/presentation/2021/march/PDSB_Corporate_Overview_-_March_11_2021_FINAL_1.pdf
PDSB Bleeding edge 2.0 Versamune®-based immunotherapies. technology for Cancer & infectious diseases This is a multibillion possibly double digit billion market cap in the making in the next 12-24 months buy and hold LONG TERM.
$MRNA 55 Billion market cap
$NVAX 16 Billion market cap
$OCGN 1.5 Billion market cap
$PDSB 115 million market cap (second generation CV-19 vaccine for Brazil and America
Diamond Hands PDSB Investors if you hold and buy more this will be trading double digits soon. Don't forget to lock up your shares GTC Good till cancelled month on out.
$PDSB
India and $OCGN approved their homegrown vaccine through Bharat during phase 3 trials for emergency use before data was even released.
Brazil could easily do the same thing with PDSB second generation CV-19 PDSB 0203 They want their own homegrown vaccine in Brazil make no mistake about it.
Franks timeline has to be published according to normal timetables but there is a distinct possibility PDS 0203 could get An EUA by the end of this year or Q1 22 if it follows what India did.
$OCGN went from .17-$18.77 (188 Million shares 1.65 Billion market cap 9x the shares outstanding compared to PDSB.
Normalcy will return only with second generation of Covid-19 vaccine: Bill Gates
PDSB Development of PDS0203 offer's potential advantages as a
Second Generation COVID-19 vaccine.
May be effective against multiple COVID-19 variants
Demonstrated induction of killer CD8+ and helper CD4+ T cells that can target less variable regions of the SARS-CoV-19 virus and may be effective against currently circulating variants.
VERSAMUNE PLATFORM
• NCI-initiated phase 2 HPV-cancer trial
surpassed initial efficacy requirement
prompting expansion to full enrollment
• Novel COVID-19 vaccine being developed
in Brazil with consortium partners
• MCTI, Brazil to fund COVID-19 vaccine
manufacturing scale up & clinical trials
• Demonstrated to work with a wide array of
oncogenes and viral antigens
• Multiple composition and application
patents valid through mid-2030s
PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of PDS0203 with an Award of up to ~US$60 Million
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/501-iotechnnouncesthatits19accineonsortium20210311n
As PDSB VERSAMUNE®
PLATFORM progresses their CV-19 Vaccine the share price will go up Phase 3 in Q4 of 2021 This is a big deal. Revenue coming in sooner than later from the CV-19 vaccine allowing to fund and expand their cancer platform and infectious disease platform. Market cap should be between 1.5 to 2 Billion at least on CV-19 approval Vaccine for Brazil & then opening up more markets in South America.
$MRNA 57 Billion market cap
$NVAX 17 Billion market cap
$OCGN 1.65 Billion market cap
$PDSB 120 million market cap (second generation CV-19 vaccine for Brazil and America
$PDSB
PDSB Development of PDS0203 offer's potential advantages as a
Second Generation COVID-19 vaccine.
May be effective against multiple COVID-19 variants
Demonstrated induction of killer CD8+ and helper CD4+ T cells that can target less variable regions of the SARS-CoV-19 virus and may be effective against currently circulating variants.
May grant long-lasting immunity
Demonstrated induction of long-lasting, virus-specific memory T-cells necessary for longer term protection.
High potential for safety
PDS0203 is a subunit vaccine, and does not require the use of attenuated viruses,traditional adjuvants, DNA or RNA. Versamune®-based vaccines have shown no serious or
dose limiting reactions.
Normalcy will return only with second generation of Covid-19 vaccine: Bill Gates
In June 2020, PDS Biotechnology and Farmacore Biotechnology announced the co-development of a potential COVID-19 Vaccine based on the Versamune platform. This partnership allowed them to quickly accelerate towards Phase 1 trials in Brazil. The vaccine candidate (Versamune-CoV-2FC) was designed to provide rapid induction of neutralizing antibodies, as well as killer T-cells and memory T-cells against COVID-19, and to prevent the spread of infection.
In a March 2021 press release, PDS announced that their vaccine consortium had received a commitment from the Ministry of Science, Technology and Innovation of Brazil to fund clinical development and commercialization. This award (~$60MM) was based on pre-clinical studies which showed strong potential to induce immune responses against the virus. Phase 1 and 2 trials to assess safety and efficacy will run together in Brazil, and are expected to enroll 360 pateints.
“PDS Biotech and Farmacore Biotechnology have taken the important step of advancing our Versamune®-based COVID-19 vaccine into the clinic,” said Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech.“ The pre-clinical results demonstrate the vaccine’s potential to induce a broad range of robust anti SARS-CoV-2 immune responses. The rapidly increasing number of SARS-CoV-2 mutations highlights the need for novel, second generation vaccines capable of generating both killer and helper T-cells that can recognize and attack conserved and non-mutating regions of the virus. We applaud Farmacore Biotechnology and Blanver Farmoquímica for reaching this important milestone and look forward to the results of the planned human clinical trials and hopefully a rapid advancement towards commercialization of the product. These clinical trials will also advance our understanding of the potential for novel Versamune®-based vaccines to provide long-term protection against infection with viruses with pandemic potential such as SARS-CoV-2.”
MRNA 60 Billion market cap
NVAX 16 Billion market cap
PDSB 112 Million market cap
Greater quantity and quality of Versamune®-induced killer T-cells mayresult in unique ability to eradicate HPV-positive tumors after a single dose
PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of PDS0203 with an Award of up to ~US$60 Million
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/501-iotechnnouncesthatits19accineonsortium20210311n
Multiple Peer Reviewed papers:
1.Journal for Immuno Therapy of Cancer:
https://jitc.bmj.com/content/8/1/e000612
2.the Journal of Immunology:
https://www.jimmunol.org/content/202/12/3524
PDSB White Paper:
https://pdsbiotech.com/images/pdf/presentation/2021/Whitepaper-2021_v6.pdf
PDSB website:
https://pdsbiotech.com/
PDSB March 2021 Biz presentation:
https://www.pdsbiotech.com/images/pdf/presentation/2021/march/PDSB_Corporate_Overview_-_March_11_2021_FINAL_1.pdf
PDS Biotech preparing to initiate 3 phase 2 clinical Cancer studies for lead candidate PDS0101
Diamond hands double digits sooner than later Phase 3 CV-19 vaccine starts in quarter 4 2021 approval 2022 commercialization by 2023
Triple digits on approved second generation CV—19 variants vaccine.
Bleeding cutting edge oncology platform partnered with NIC MD Anderson and Merck.
Low burn rate no debt 22 million shares outstanding Institutions and insiders own over 42% some revenue will be coming in on the 60 million from Brazil PDSB will get a slice to consult on the buildout.
115 million market cap hundreds of millions in revenue next 18 months 2.0 CV-19 vaccine focuses on South America Brazil wants there own in house CV-19 vaccine. It’s coming!
So impressed with Frank and the team at PDSB.
Multi billion market cap on approval of the CV-19 vaccine.
$PDSB
PDSB our first double digit Price Target yall! $12.00 at OPPENHEIMER.
PDS Biotechnology Corp (PDSB) PT Raised to $12.00 at Oppenheimer
https://www.streetinsider.com/Analyst+Comments/PDS+Biotechnology+Corp+%28PDSB%29+PT+Raised+to+%2412+at+Oppenheimer+%28Earlier%29/18152769.html
$PDSB
HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Raises Price Target to $8.00
Benzinga Newdesk ,
March 19, 2021 6:46am
$PDSB
PDSB Second generation CV-19 vaccine to neutralize the antibodies as well as CD4 helper T-cells and CD8 killer T-cells against SARS-CoV-2.
First generation vaccines don't work that well or at at all with some strains against the many CV-19 Variants.
From the transcript earnings call this morning from the CEO:
the Brazilian market represents a potential multibillion dollar revenue opportunity based on its population of 213 million people and reported COVID-19 vaccine pricing of approximately $20 to $74 for a two dose regimen. Outside of Brazil our development partner Farmacore also has the rights to commercialize PDS0203 throughout Latin America, which increases this market potential by approximately three times based on the population.
In summary, this announcement has two important financial implications for PDS. First, it provides near term financial support for our clinical and scale up activities for PDS0203. And second, it represents a significant revenue potential starting in 2023 based on the commercialization of PDS0203 if the planned clinical trials are successful.
Brazil records more than 90,000 new COVID cases in a single day
Brazilian President Bolsonaro faces mounting pressure as coronavirus infections and deaths continue to mount.
https://www.aljazeera.com/news/2021/3/17/brazil-records-over-90000-new-covid-cases-in-a-single-day
3 Phase 2 Cancer Trials Partnered with: (Billion dollar Markets).
1. Merck
2. MD Anderson Cancer Center
3. National Institute of Cancer
Brazil health service in 'worst crisis in its history'
https://www.bbc.com/news/world-latin-america-56424611
Brazil’s rolling coronavirus disaster is a global problem.
https://www.washingtonpost.com/world/2021/03/17/brazil-coronavirus-disaster-bolsonaro/
Part of the problem is the emergence of a more virulent coronavirus variant in Brazil, one whose rapid spread since January has raised global alarm. “If Brazil is not serious, then it will continue to affect all of the neighborhood there — and beyond,” Tedros Adhanom Ghebreyesus, director general of the World Health Organization, warned earlier this month. “This is not just about Brazil. It’s about the whole Latin America, and even beyond.”
PARIS LOCKED FOR MONTH
THIRD WAVE WRECKS SPRING
WHEN WILL THIS END?
MRNA 60 Billion market cap
NVAX 16 Billion market cap
PDSB 105 Million market cap
PDSB 22 million shares outstanding 42% owned by institutions & insiders less than 14 million floating. Hence there are very few shares available. They are Limited & scarce and have the potential to be worth $200.00+ in 24 months or less. On approved second generation CV-19 vaccine focused on Latin America 3/4 of a billion people.
PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of PDS0203 with an Award of up to ~US$60 Million
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/501-iotechnnouncesthatits19accineonsortium20210311n
PDSB Website
https://www.pdsbiotech.com/
PDSB March Biz Presentation March 2021
https://www.pdsbiotech.com/images/pdf/presentation/2021/march/PDSB_Corporate_Overview_-_March_11_2021_FINAL_1.pdf
$PDSB
29 Million still in cash this team is frugal & top notch with skin the game insiders & tutes own over 42% of the shares.
Accumulate what you can at these levels these prices won't last much longer.
22 million outstanding shares 14 million floating 75 million plus traded since 1st of Feb. Scant amount of shares are available don't get robbed for your shares.
Revenue consulting fees from the 60 million. Genius they have Brazil and farmacore and blander handle everything logistically get the funds for the trials and manufacturing PDSB has so much revenue potential from this second generation vaccine. And they still get to focus on the Cancer Oncology trials that are worth Billions in total. This company could realistically 100x-150x from these levels at 112 million market cap. 10-20 Billion market cap potential here with PDSB look at NVAX and MRNA market caps. NVAX was 8.00 in the last 12 months and went to a high of 331.00. There vaccine isn't even all that.
MRNA 60 Billion market cap
NVAX 16 Billion market cap
PDSB 112 Million market cap
PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of PDS0203 with an Award of up to ~US$60 Million
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/501-iotechnnouncesthatits19accineonsortium20210311n
PDSB Website
https://www.pdsbiotech.com/
PDSB March Biz Presentation
https://www.pdsbiotech.com/images/pdf/presentation/2021/march/PDSB_Corporate_Overview_-_March_11_2021_FINAL_1.pdf
$PDSB
Buy what ever PDSB shares you can at these levels.
This is going to go parabolic soon and go to double digits and then triple digits by sometime in 2022-2023 BUY AND HOLD GTC your shares.
There are no shares left to buy at these prices $10.00-$20.00 is coming. Don't sell for a few bucks to then chase PDSB higher.
PDSB has 14 million shares floating 22 million outstanding.
42% owned by institutions and insiders.
These shares are limited and will be worth a hefty premium soon.
Reminder 75 million shares traded since the beginning of Feb. 6x the float Savvy biotech investors are stashing their shares for thousand percent gains.
Buy what ever you can and hold for 24 months for max profits after tax on capital gains is minimal compared to short term gains.
You buy decent amount you can be multi millionaire IMO from these levels.
NVAX went from $8.00-331.00 in a year. 16.5 Billion market cap
PDSB 111 million market cap superior technology to NVAX I believe we can see the same type of move and market cap in the next 12-24 months. Thats 170x ROI from PDSB 111 market cap similar share structure to NVAX much superior team and tech its coming as the CV-19 Variant vaccine and Cancer oncology programs march forward.
Phase 3 begins Q4 2021 CV-19 Vaccine in Brazil
The second generation CV-19 vaccine for South America populations
PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of a Versamune®-Based COVID-19 Vaccine with an Award of up to Approximately US$60 million
https://www.globenewswire.com/news-release/2021/03/11/2191396/0/en/PDS-Biotech-Announces-that-its-COVID-19-Vaccine-Consortium-Received-a-Commitment-from-The-Ministry-of-Science-Technology-and-Innovation-of-Brazil-MCTI-to-fund-Clinical-Development-.html
PDS Biotechnology
Oppenheimer 31st Annual Healthcare Conference
March 16, 2021
https://wsw.com/webcast/oppenheimer9/pdsb/2708189
PDSB March 2021 Biz presentation.
https://pdsbiotech.com/images/pdf/presentation/2021/march/PDSB_Corporate_Overview_-_March_11_2021_FINAL_1.pdf
$PDSB
Quarter 4 2021 Initiation of Phase 3 COVID Vaccine clinical trial of PDS0203 the value of that is much higher than the price per share today!
Development of PDS0203 may offer potential advantages as a second generation COVID-19 vaccine
May be effective against multiple COVID-19 variants
Demonstrated induction of killer CD8+ and helper CD4+ T cells that can target less variable
regions of the SARS-CoV-19 virus and may be effective against currently circulating
variants.
May grant long-lasting immunity
Demonstrated induction of long-lasting, virus-specific memory T-cells necessary for
longer term protection.
High potential for safety
PDS0203 is a subunit vaccine, and does not require the use of attenuated viruses,
traditional adjuvants, DNA or RNA. Versamune®-based vaccines.
Have shown no serious or
dose limiting reactions.
Validation of approach: All three on-going phase 2 Oncology clinical trials supported and partnered with leading and
top-tier institutions in the field of cancer and immuno-oncology
I added over 50k shares today to my stash now across 3 different stock accounts and an IRA today thats how much I believe this company is a 50x-100x ROI in a few years from now. on the Covid Vaccine & oncology programs.
Buy all you can at these levels this really can double or triple in a blink of an eye.
Don't forget to put in a sell order for months out at $100.00+ for your shares.
Phase 3 CV-19 Vaccine that can handle the variants and possible preventive vaccine is worth BILLIONS the price will surge soon you can make book on that!
$PDSB
Put your shares GTC for $100.00 so these MM can't short your shares!
PDSB over 75 Million SHARES Traded since February 1st commenced there is about 14 million shares FLOATING. Lock up your shares Good till cancelled months out from today.
42% owned by insiders & institutions.
22 million shares minus shares owned by insiders & tutes
Equals less than 14 million shares Floating 111 million market cap tremendous upside 50x-100x ROI Potential in 2 years.
These MM are spoof trading this stock. Trying to rattle impatient folks. If you do the math there is really no liquid shares out there. They are trying so hard to accumulate this stock. I really believe we will be well into the double digits sooner than later.
The Covid Variant situation in Brazil and South America is spiraling out of control. This vaccine is worth 20 billion or more when approved late next year commercial ready in 2023 emergency EUA could be sooner.
Brazil’s rolling coronavirus disaster is a global problem
https://www.msn.com/en-us/news/world/brazil-e2-80-99s-rolling-coronavirus-disaster-is-a-threat-to-the-world/ar-BB1eFhPN
Bolsonaro’s Standing Craters Amid Historic Health-Care Collapse
https://www.bloombergquint.com/onweb/bolsonaro-s-rejection-soars-amid-historic-healthcare-collapse
PDSB has multi hundred dollar share price potential like NVAX or MRNA
PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of PDS0203 with an Award of up to ~US$60 Million
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/501-iotechnnouncesthatits19accineonsortium20210311n
PDSB Website
https://www.pdsbiotech.com/
PDSB March Biz Presentation
https://www.pdsbiotech.com/images/pdf/presentation/2021/march/PDSB_Corporate_Overview_-_March_11_2021_FINAL_1.pdf
PDSB Bleeding edge 2.0 Versamune®-based immunotherapies. technology for Cancer & infectious diseases This is a multibillion possibly double digit billion market cap in the making in the next 12-24 months buy and hold LONG TERM.
$PDSB
Consolidating for the next leg up.
Diamond Hands.
$PDSB
ZW Data Action Technologies (CNET) Entered into Strategic Cooperation Agreement with China Digital Culture for the Introduction of DeFi into the Fasting Growing Esports and Game Data Operation.
ZW Data and Digital Culture strive to introduce Defi, built on both Ethereum and Polkadot, into esports and game data operation, combining ZW Data’s KOL and O2O sales channel for additional revenue growth.
https://www.streetinsider.com/Corporate+News/ZW+Data+Action+Technologies+%28CNET%29+Entered+into+Strategic+Cooperation+Agreement+with+China+Digital+Culture+for+the+Introduction+of+DeFi+into+the+Fasting+Growing+Esports+and+Game+Data+Operation/17927933.html
BTC
Blockchain
BTC Bitcoin Mining
E Gaming DEFI Decentralized Finance Blockchain
$CNET
Took a starter here like the blockchain, crypto & bitcoin mining angle.
Small float.
Micro market cap.
Nasdaq Listing.
Retest of 52 week high 6.19 and possible double digits later in 2021
Chart looks great for much further upside continuation.
Could see parabolic price movement like Mara & Riot sooner than later.
ZW Data Action Technologies Partner with BitSpace for Joint Blockchain Mining Platform
https://www.globenewswire.com/news-release/2021/02/10/2173057/0/en/ZW-Data-Action-Technologies-Partner-with-BitSpace-for-Joint-Blockchain-Mining-Platform.html
ZW Data Action Technologies Initiates Supply Chain Finance with Digital Asset and Crypto Payment.
https://www.globenewswire.com/news-release/2021/02/02/2168195/0/en/ZW-Data-Action-Technologies-Initiates-Supply-Chain-Finance-with-Digital-Asset-and-Crypto-Payment.html
Diamond Hands.
https://tenor.com/view/clean-up-diamond-precious-hand-gif-15513141
$CNET
Diamond Hands.
https://tenor.com/view/clean-up-diamond-precious-hand-gif-15513141
$PDSB
Copy that not sure if she is I know they still hold a boat load of shares.
$SURF
Brazil plunges into deadliest chapter...
'Covid taking over'...
Third wave sweeps across EU and forces new restrictions...
German cases revisit December peak...
Merkel's party profiting from face mask deals?
Paris faces new lockdown as ICUs fill up...
Hold the line be patient add more at these levels. Don't let the MM rob you of your shares.
$PDSB
AVEO RED to GREEN.
Make shorts pay teach them a lesson for shorting cutting edge cancer platform.
Bullish Pattern Now.
New 52 week highs and then all time highs in 2021
I told you SHORTS are going to get REKT!
Don't short promising monoclonal antibodies molecules for cancer.
https://www.aveooncology.com/product-candidates/av-203/
https://www.aveooncology.com/product-candidates/av-380/
https://www.aveooncology.com/product-candidates/av-353/
AVEO Pipeline
https://www.aveooncology.com/product-candidates/pipeline/
FDA approved Drugs BIG Pharma Partnerships Small Cap Small Float.
AVEO 28 million shares half owned by institutions.
Cash runway through 2022.
AVEO Plus revenue now from FDA approved Drugs.
$AVEO
AVEO Pipeline 10 cancer oncology drugs including FDA approved indications.
Crown jewel is the 3 monoclonal antibodies: AV-203 AV-380 AV-353
https://www.aveooncology.com/product-candidates/pipeline/
Accumulating at these levels.
AVEO will most likely get bought out from Big Pharma.
AVEO 330 Million market cap
28 million shares low float.
Shorts are about to get REKT you can make book on that!
$AVEO
Hold the line don't sell!
$PDSB
Hold the Line.
Don't let clown trader chart goon guy steal your hard earned money.
$PDSB
Reloaded $69.00-$71.00 will ride it to new highs.
$BEAM
Where is that Bozo clown trader the chart guy LOL LMAO
$PDSB
Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
How about Them apples!!!
Banking Hard!
Hold the line!!!!
$PDSB
I agree share price will be higher like to see the 30 million in cash PDSB has now move to 100 million plus in the bank.
$PDSB
Please PDSB investors when the company does another offering PLEASE DON"T PANIC we need more cash and that will be the last component to launch this company to the next level. It will be great for the long term share price of this company. I could actually see the price going up after when ever they do another offering in PDSB case.
DIAMOND HANDS!
$PDSB
shorts are getting caught with their pants down again not a pretty site.
holding just under 100k Shares BOOMAGE! average cost in the 2.00's
$PDSB
Looks Like PDSB is about to surge!
Boomage!
PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of a Versamune®-Based COVID-19 Vaccine with an Awa
Development and commercialization of novel T-cell activating vaccine to be performed in Brazil by consortium of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica
FLORHAM PARK, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on PDS Biotech’s proprietary Versamune® T-cell activating technology, today announced that its COVID-19 vaccine consortium consisting of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica, has received a commitment from the Secretary for Research and Scientific Training of the MCTI to fund up to approximately US$60 million to support the clinical development and commercialization of a novel, Versamune®-based, second generation COVID-19 vaccine in Brazil.
MCTI intends to start making the funds available to prepare to perform a combined Phase 1/2 clinical trial, upon authorization by the Brazilian regulatory agency, Agência Nacional de Vigilância Sanitária (Anvisa) to initiate the proposed Versamune®-based COVID-19 vaccine clinical program in Brazil.
The pre-IMPD package for the Phase 1/2 trial is currently under review by Anvisa and the trial is anticipated to begin by Q2/3 2021. The majority of the capital provided by MCTI will fund the manufacturing process scale up, production and the Phase 3 trial, pending the results of the Phase 1/2 trial. The consortium members will work under a mutually agreed work plan to guide the vaccine efficiently through development in compliance with regulatory standards. The consortium anticipates working to initiate manufacturing scale up activities in the second quarter.
This award is based on the preclinical studies of the Versamune®-based COVID-19 vaccine. The vaccine combines PDS Biotech’s Versamune® T-cell activating platform technology with a SARS-CoV-2 recombinant protein derived from the spike (S) protein. Notably, the protein in this fully synthetic vaccine includes conserved and non-mutating regions of the virus. The vaccine has demonstrated strong potential in preclinical studies to efficiently promote the induction of killer (CD8+) and helper (CD4+) T-cells that recognize and induce immune responses against such non-mutating regions of the virus. The protein also includes regions of the spike protein that result in the induction of neutralizing antibodies.
The Phase 1 and 2 trials, which will be run together, are anticipated to enroll approximately 360 patients and will assess the safety and efficacy of the vaccine as well as both the antibody and killer T-cell responses induced by the vaccine to the novel coronavirus. The clinical trials are planned to be conducted in Brazil.
“PDS Biotech and Farmacore Biotechnology have taken the important step of advancing our Versamune®-based COVID-19 vaccine into the clinic,” said Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech.“ The preclinical results demonstrate the vaccine’s potential to induce a broad range of robust anti SARS-CoV-2 immune responses. The rapidly increasing number of SARS-CoV-2 mutations highlights the need for novel, second generation vaccines capable of generating both killer and helper T-cells that can recognize and attack conserved and non-mutating regions of the virus. We applaud Farmacore Biotechnology and Blanver Farmoquímica for reaching this important milestone and look forward to the results of the planned human clinical trials and hopefully a rapid advancement towards commercialization of the product. These clinical trials will also advance our understanding of the potential for novel Versamune®-based vaccines to provide long-term protection against infection with viruses with pandemic potential such as SARS-CoV-2.”
“We are excited to continue advancing the program with PDS Biotech, and we are thrilled to have had the continued support of the Brazilian government as we finalize clinical study protocols with Anvisa for human testing of the novel vaccine combining the Versamune® T-cell activating technology with the SARS-CoV-2 recombinant protein antigen. We are proud to advance this promising medicine in Brazil in the fight against this global pandemic,” said Helena Faccioli, CEO of Farmacore Biotechnology.
As the license holder of PDS0203 in Latin America, Farmacore Biotechnology will continue to lead the regulatory and clinical trial efforts in Brazil and has selected a top clinical research organization, to conduct clinical trials in Brazil. PDS Biotech will continue to contribute scientific expertise and operational support and oversee scale up of the manufacturing process. Blanver Farmoquímica will manufacture, promote, distribute, and commercialize the Versamune®-based COVID-19 vaccine in Latin America.
All funding is contingent on the availability of financial resources within the MCTI, and The Secretary for Research and Scientific Training of the MCTI has committed to making every effort to finance all clinical and development stages of the program.
$PDSB
$PDSB
Loaded again!
$188.89 Yesterday
$GME
Shorts are Toast! I smell burned bear meat.
$AVEO
Boomage Shorties stick a fork in it!!!!
$AVEO
top tier Cancer plays are going to be Bigly in 2021.
$AVEO
waiting to see if there is a complete melt down across the board on the nasdaq. Thinking Nasdaq under 10k is in the cards.
$SURF
I will load up more if it gets to those levels.
$MMEDF
2.59 Resistance broken.
MMEDF Markets tank $1.40 bottom possibility for MMEDF.
Cheers.
$PDSB
Brazil's hospitals reach breaking point as health minister blames new coronavirus variants.
https://www.cnn.com/2021/03/01/americas/brazil-hospitals-coronavirus-variants-blame-intl-latam/index.html
PDSB has the the best second generation CV-19 Vaccine for south America = Bigly!
PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine
PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency
$PDSB
VTGN Institutional Shares have skyrocketed to 61% this year.From 7% last year.
Cash runway into 2023
Multiple offers on the table for VTGN companies want a blockbuster next generation low side effects fast acting depression and anxiety drugs 16 drugs in the pipeline massive.
VTGN has all the boxes checked off. 115 million plus cash in the bank.
Deep pipeline 16 drugs next generation depression and anxiety meds.
VTGN fast acting 15 min & low side effects.
First generation depression meds have a 30% success rate at best very high side effects & takes months to start to take effect.
VTGN Phase 3 ready Fast tracked. Social Anxiety Disorder.
Multiple phase 2's including VistaGen PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)
VTGN multi billion dollar depression/anxiety pipeline Be Patient & add at these levels. If Mindmed is valued at 1 Billion market capitalization roughly 30 million in cash nearing phase 2B is MMEDF furthest drug out in trials.
VTGN 115 million in cash market cap 360 million Phase 3 Ready Anxiety low side effects fast acting and a phase 2 Covid fast tracked indication for depression starting early 2021 both. fast tracked. This stock probably be 20.00+ 2021-2022 Buy and hold. multi Billion dollar market cap in the making.
next generation depression and anxiety drugs is a smart place to be invested for massive ROI.
World renown psychologists Michael Liebowitz heading VTGN trials is this very valuable resource to VTGN
https://ir.vistagen.com/press-releases/detail/98/vistagen-therapeutics-appoints-dr-michael-liebowitz-to-cns He developed the
Liebowitz scale he is heading all our trials for VTGN
https://nationalsocialanxietycenter.com/liebowitz-sa-scale/
Biogen bets on depression drug in $1.5 billion deal with Sage Therapeutics
https://www.reuters.com/article/us-biogen-sage/biogen-bets-on-depression-drug-in-1-5-billion-deal-with-sage-therapeutics-idUSKBN2871GU
https://www.who.int/news/item/05-10-2020-covid-19-disrupting-mental-health-services-in-most-countries-who-survey
VTGN Pipeline:
https://www.vistagen.com/pipeline
VTGN Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_78f83b9b022497768da4a497c4d9e5b2/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+2020_11_16+250pm+PT.pdf
VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Anxiety depression peers:
$CMPS 2 billion market cap early clinical trials. 190 million cash
$MMEDF 1.2 billion market cap.
$SAGE 3 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 357 million market cap Phase 3 ready. (nasdaq)
115 million in cash
Depression and anxiety one of the most sought after sector in biotech large population of people in the world are depressed.
93% increase in people participating in anxiety screenings, according to Mental Health America.
$VTGN
new 52 week highs and then some in sight. Boomage
$MARA
VTGN there is a bidding war behind the scenes for VTGN this is going to get interesting real fast. BOOMAGE. Multiple big pharma companies making offers for VTGN
$VTGN